Results 141 to 150 of about 9,857 (174)

Reply to Feng, "Recalculation of inhibitor concentration fold-changes for CMY-219: comments on a recent article about CMY-219 conferring resistance to ceftazidime-avibactam". [PDF]

open access: yesAntimicrob Agents Chemother
Jousset AB   +10 more
europepmc   +1 more source

In Vitro Comparison of Aztreonam/Amoxicillin-Clavulanate Versus Aztreonam/Ceftazidime-Avibactam on Ceftazidime-Avibactam Resistant Stenotrophomonas maltophilia

Microbial Drug Resistance, 2022
We investigated the in vitro susceptibility of ceftazidime-avibactam (CZA) resistant Stenotrophomonas maltophilia to the associations aztreonam/amoxicillin-clavulanate (ATM-AMC) and ATM-CZA. Forty clinical isolates of S. maltophilia
Crémet, Lise   +6 more
openaire   +4 more sources

The primary pharmacology of ceftazidime/avibactam: resistancein vitro

Journal of Antimicrobial Chemotherapy, 2023
AbstractThis article reviews resistance to ceftazidime/avibactam as an aspect of its primary pharmacology, linked thematically with recent reviews of the basic in vitro and in vivo translational biology of the combination (J Antimicrob Chemother 2022; 77: 2321–40 and 2341–52).
Wright W Nichols   +3 more
openaire   +2 more sources

Ceftazidime/avibactam‐induced severe neutropenia: A case report

British Journal of Clinical Pharmacology, 2023
AbstractCeftazidime/avibactam is an important option for the treatment of infections caused by multidrug‐resistant gram‐negative bacteria. Haematological abnormalities are rare adverse events. We describe a case of a 63‐year‐old male who developed severe neutropenia following exposure to ceftazidime/avibactam in the intensive care unit for the ...
Weifang Wu   +3 more
openaire   +2 more sources

Microbiological interaction studies between ceftazidime-avibactam and pulmonary surfactant and between ceftazidime-avibactam and antibacterial agents of other classes

International Journal of Antimicrobial Agents, 2014
For an antibacterial agent to be considered for clinical studies in nosocomial pneumonia (NP), it should be active in the presence of pulmonary surfactant. Furthermore, owing to the common practice of treating such infections with more than one antibacterial agent, it should be free of antagonistic interactions with agents of other classes.
John, Dallow   +4 more
openaire   +2 more sources

Ceftazidime/avibactam experience in tertiary hospital in Türkiye

Kastamonu Medical Journal, 2023
Aims: Real-life experience with ceftazidime/avibactam in the treatment of multidrug-resistant Klebsiella pneumoniae is still limited. This retrospective study aims to evaluate the efficacy of ceftazidime/avibactam in the treatment of critically ill patients with infections due to carbapenem-resistant pathogens.
Alper Tahmaz, Ayşegül Seremet Keskin
openaire   +1 more source

Ceftazidime/Avibactam: A New Antibiotic for Gram-Negative Infections

The Consultant Pharmacist, 2015
To review the chemistry, pharmacology, microbiology, pharmacokinetics, pharmacodynamics, clinical efficacy, safety, dosing, and administration of ceftazidime/avibactam (CAZ/AVI).A search of PubMed using the terms "ceftazidime," "avibactam," "NXL104," and "AVE1330A" was performed. The manufacturer's website was also reviewed to further identify relevant
Elias B, Chahine   +2 more
openaire   +2 more sources

Ceftazidime/avibactam serum concentration in patients on ECMO

Journal of Antimicrobial Chemotherapy
Abstract Objectives The use of extracorporeal membrane oxygenation (ECMO) may alter blood levels of several drugs, including antibiotics, leading to under dosing of these drugs and thus to potential treatment failure.
Anaïs Curtiaud   +7 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy